Thanh Trung Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thanh Trung Nguyen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Huu Dat Nguyen
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
4 shared publications - Young Eun Kim
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
4 shared publications - Hoang Bao Tram Tran
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
2 shared publications Hye Joung Choi
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
2 shared publications- Hye Joung Choi
Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang-si, Republic of Korea
2 shared publications - Hyeo-Il Ma
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
2 shared publications
Latest Publications
- 21 September 2026
- Published by Wiley in Movement Disorders
Urine‐Derived Neuronal Extracellular Vesicle α ‐Synuclein Seed Amplification Assay for Synucleinopathies: A Non‐Invasive Biomarker Study
Background: α ‐Synuclein aggregation is a pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). Although pathogenic α ‐synuclein seeds can be detected by real‐time quaking‐induced conversion (RT‐QuIC), current assays primarily rely on cerebrospinal fluid, whose invasiveness limits repeated and large‐scale applications. We therefore evaluated the feasibility of detecting pathogenic α ‐synuclein using urine‐derived neuronal extracellular vesicles (NEVs). Methods: Urine‐derived NEVs were enriched by direct immunoprecipitation using L1CAM‐conjugated magnetic beads. The RT‐QuIC assay was performed in 26 patients with PD, 13 with MSA, and 25 disease controls, including 16 healthy controls (HC), 4 with progressive supranuclear palsy (PSP), and 5 with normal pressure hydrocephalus (NPH). Results: Urine‐derived NEVs exhibited characteristic neuronal and exosomal markers and a typical extracellular vesicle size distribution. The urine‐based RT‐QuIC assay distinguished PD from disease controls with 73.1% sensitivity and 84% specificity, and MSA from disease controls with 76.9% sensitivity and 84% specificity. When compared with HC alone, sensitivity and specificity were 73.1% and 93.8% for PD, and 76.9% and 93.8% for MSA, respectively. Kinetic analysis showed higher maximum fluorescence intensity and area under the curve (AUC) in PD compared with both disease controls and HC ( P < 0.001 in all). MSA also demonstrated higher maximum fluorescence intensity than HC and increased AUC compared with both disease controls and HC ( P < 0.05 in all). Conclusions: We developed and optimized a completely non‐invasive urine‐derived NEV α ‐synuclein RT‐QuIC assay that demonstrates high specificity and moderate sensitivity for synucleinopathies. This approach warrants further validation in larger cohorts. © 2026 International Parkinson and Movement Disorder Society.
- 21 September 2026
- Published by Wiley in Movement Disorders
Urine‐Derived Neuronal Extracellular Vesicle α ‐Synuclein Seed Amplification Assay for Synucleinopathies: A Non‐Invasive Biomarker Study
Background: α ‐Synuclein aggregation is a pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). Although pathogenic α ‐synuclein seeds can be detected by real‐time quaking‐induced conversion (RT‐QuIC), current assays primarily rely on cerebrospinal fluid, whose invasiveness limits repeated and large‐scale applications. We therefore evaluated the feasibility of detecting pathogenic α ‐synuclein using urine‐derived neuronal extracellular vesicles (NEVs). Methods: Urine‐derived NEVs were enriched by direct immunoprecipitation using L1CAM‐conjugated magnetic beads. The RT‐QuIC assay was performed in 26 patients with PD, 13 with MSA, and 25 disease controls, including 16 healthy controls (HC), 4 with progressive supranuclear palsy (PSP), and 5 with normal pressure hydrocephalus (NPH). Results: Urine‐derived NEVs exhibited characteristic neuronal and exosomal markers and a typical extracellular vesicle size distribution. The urine‐based RT‐QuIC assay distinguished PD from disease controls with 73.1% sensitivity and 84% specificity, and MSA from disease controls with 76.9% sensitivity and 84% specificity. When compared with HC alone, sensitivity and specificity were 73.1% and 93.8% for PD, and 76.9% and 93.8% for MSA, respectively. Kinetic analysis showed higher maximum fluorescence intensity and area under the curve (AUC) in PD compared with both disease controls and HC ( P < 0.001 in all). MSA also demonstrated higher maximum fluorescence intensity than HC and increased AUC compared with both disease controls and HC ( P < 0.05 in all). Conclusions: We developed and optimized a completely non‐invasive urine‐derived NEV α ‐synuclein RT‐QuIC assay that demonstrates high specificity and moderate sensitivity for synucleinopathies. This approach warrants further validation in larger cohorts. © 2026 International Parkinson and Movement Disorder Society.
- 11 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1383
TP53 status is associated with differential stress-marker expression and APP maturation in colon cancer cells
- 11 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1383
TP53 status is associated with differential stress-marker expression and APP maturation in colon cancer cells
- Open Access
- 31 January 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (1) , 31-38
Differential Peripheral NLRP3 Inflammasome Expression in Patients With Parkinson’s Disease and Patients With Multiple System Atrophy
Objective The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has been proposed to be a downstream mediator of neuroinflammation in individuals with Parkinson’s disease (PD). However, its involvement across disease stages and related synucleinopathies, such as multiple system atrophy (MSA), remains unclear. We aimed to analyze the peripheral mRNA expression of NLRP3-related genes and cytokines across individuals with isolated REM sleep behavior disorder (iRBD), early-stage PD, late-stage PD, and MSA.Methods Peripheral blood mononuclear cells (PBMCs) were collected from 151 participants: 35 healthy controls (HCs), 31 patients with iRBD, 41 patients with early-stage PD, 21 patients with late-stage PD, and 23 patients with MSA. mRNA expression was measured using quantitative real-time polymerase chain reaction. Statistical comparisons were performed using analysis of variance (ANOVA) or Welch’s ANOVA, and associations with clinical variables were analyzed through stepwise multiple linear regression.Results NLRP3 expression was significantly lower in patients with iRBD (p=0.0263) and patients with early-stage PD (p= 0.0101) than in HCs. NIMA-related kinase 7 (NEK7) expression progressively decreased across the disease spectrum (HCs vs. patients with early-stage PD, p=0.0008; vs. patients with late-stage PD, p<0.0001). In contrast, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and caspase-1 were elevated in patients with PD, especially those in the late stages. Levels of patients with MSA resembled those of HCs but differed from those of patients with PD. Interleukin (IL)-1β and IL-18 levels were not significantly different. In patients with early-stage PD, NLRP3 expression was negatively correlated with disease duration, the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part II score, and the cognitive score.Conclusion Our findings challenge the prevailing hypothesis that NLRP3 inflammasome activation directly contributes to PD pathogenesis. Instead, the observed increase in ASC and caspase-1 expression suggests the potential involvement of alternative inflammasome pathways during disease progression.
- 31 January 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (1) , 31-38
Open AccessDifferential Peripheral NLRP3 Inflammasome Expression in Patients With Parkinson’s Disease and Patients With Multiple System Atrophy
Objective The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has been proposed to be a downstream mediator of neuroinflammation in individuals with Parkinson’s disease (PD). However, its involvement across disease stages and related synucleinopathies, such as multiple system atrophy (MSA), remains unclear. We aimed to analyze the peripheral mRNA expression of NLRP3-related genes and cytokines across individuals with isolated REM sleep behavior disorder (iRBD), early-stage PD, late-stage PD, and MSA.Methods Peripheral blood mononuclear cells (PBMCs) were collected from 151 participants: 35 healthy controls (HCs), 31 patients with iRBD, 41 patients with early-stage PD, 21 patients with late-stage PD, and 23 patients with MSA. mRNA expression was measured using quantitative real-time polymerase chain reaction. Statistical comparisons were performed using analysis of variance (ANOVA) or Welch’s ANOVA, and associations with clinical variables were analyzed through stepwise multiple linear regression.Results NLRP3 expression was significantly lower in patients with iRBD (p=0.0263) and patients with early-stage PD (p= 0.0101) than in HCs. NIMA-related kinase 7 (NEK7) expression progressively decreased across the disease spectrum (HCs vs. patients with early-stage PD, p=0.0008; vs. patients with late-stage PD, p<0.0001). In contrast, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and caspase-1 were elevated in patients with PD, especially those in the late stages. Levels of patients with MSA resembled those of HCs but differed from those of patients with PD. Interleukin (IL)-1β and IL-18 levels were not significantly different. In patients with early-stage PD, NLRP3 expression was negatively correlated with disease duration, the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part II score, and the cognitive score.Conclusion Our findings challenge the prevailing hypothesis that NLRP3 inflammasome activation directly contributes to PD pathogenesis. Instead, the observed increase in ASC and caspase-1 expression suggests the potential involvement of alternative inflammasome pathways during disease progression.
- 8 May 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107857
Prevalence and clinical impact of alpha-synuclein pathology in idiopathic normal pressure hydrocephalus: Insights from RT-QuIC assay
- 8 May 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107857
Prevalence and clinical impact of alpha-synuclein pathology in idiopathic normal pressure hydrocephalus: Insights from RT-QuIC assay